Pleural Mesothelioma
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with pembrolizumab in patients with solid tumors (STEALTH-001).
The U.S Food and Drug Administration has accepted a priority review for a new Supplemental Biologics License Application. This could be a new era in the management of pleural mesothelioma, leading to a better future for those diagnosed with the cancer. The review is looking for approval of Keytruda used alongside chemotherapy. This combination could…
Mesothelioma, a cancer mainly caused by asbestos exposure, is typically found in older Americans. One problem with mesothelioma is that it is hard to tell between reactive and cancerous cells. A study in the American Journal of Pathology sheds light and expands on this information. The study found a biomarker, ACADL, while using advanced analysis…
This is a multicenter, single-arm, phase II clinical study to evaluate the safety and efficacy of Cadonilimab combined with gemcitabine, or vinorelbine, or pemetrexed in the treatment of patients with recurrent / refractory pleural mesothelioma.
Palliative care is an essential part of the cancer treatment process. It helps improve the quality of life of people with life threatening illnesses like mesothelioma. It is important for doctors to know the range of symptoms patients experience to help provide the best care possible. Palliative care is a specialty in medicine. The focus…
There is a debate about whether surgery for mesothelioma is beneficial. A new study was presented at the World Conference on Lung Cancer. The study looked at the survival of pleural mesothelioma patients who had different types of treatment. These included chemotherapy followed by surgery and chemotherapy only. The goal of the study was to…
This phase I/II trial studies the side effects and the best dose of methoxyamine when given together with cisplatin and pemetrexed disodium and to see how well it works in treating patients with solid tumors or mesothelioma that have spread to other places in the body and usually cannot be cured or controlled with standard treatment (advanced), or mesothelioma that does not respond to pemetrexed disodium and cisplatin or carboplatin (refractory). Methoxyamine may shrink the tumor and may also help cisplatin and pemetrexed disodium work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as cisplatin and pemetrexed disodium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving methoxyamine together with cisplatin and pemetrexed disodium may be a better treatment for solid tumors or mesothelioma than methoxyamine and pemetrexed disodium.
A recent study looked at the body’s immune system and how it responds to pleural mesothelioma, a cancer of the lining of the lungs. Results were published in the journal Pathobiology. The immune cells around the tumor area of 60 pleural mesothelioma patients were studied. The researchers used biomarkers to determine cell types and their…
Primary Outcome Measures Number of participants treated with Alintegimod monotherapy with treatment related adverse events as assessed by CTCAEv5.0 Number of participants treated with Alintegimod in combination with treatment related adverse events as assessed by CTCAEv5.0 Define RPTDs for Alintegimod Secondary Outcome Measures Characterize Pharmacokinetics of Alintegimod monotherapy by measuring Maximum Plasma Concentration (Cmax) Characterize…
Mesothelioma is a hard cancer to treat that has low survival rates. This makes it a problem for doctors and researchers. A new study is looking to change this by looking at the collagen receptor uPARAP. The current clinical trial is looking at uPARAP, a protein that is found in higher levels in mesothelioma cells.…
